NSRX Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Nasus Pharma (NYSEAMERICAN: NSRX)
›
Nasus Pharma (NYSEAMERICAN: NSRX) is listed on NYSE American, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 2.550 USD on 19 November 2026, down 62.2% over 52 weeks. Its 52-week range is 1.980 USD to 9.500 USD: the price is 73.2% below the high and 28.8% above the low.
Its market capitalisation is 29.87M USD.
Nasus Pharma reports return on equity of -211.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 11.71M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.